Targeted therapy and immunotherapy plus liver chemo for liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two treatments—a targeted pill (donafenib) and an immunotherapy drug (pucotenlimab)—along with a type of chemotherapy given directly to the liver through a catheter. The goal is to see if this combination can shrink or control liver cancer better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a diagnosis of liver cancer (hepatocellular carcinoma) that cannot be removed by surgery, or it has spread.
- You have not received any previous systemic treatment (like pills or IV drugs) for this cancer.
- You have at least one tumor that can be measured on a scan.
- You are generally active and able to take care of yourself (ECOG 0 or 1).
- Your liver and kidney function are good enough (tests will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
This trial tests a new combination of treatments for intrahepatic cholangiocarcinoma (a bile duct cancer in the liver) that cannot be surgically removed. It combines chemo directly into the liver with two drugs that boost the immune system and block blood vessel growth, hoping to shrink the tumor and help you live longer.
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.